COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes

Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation Affecting initially China, New York City (NYC) quickly became the epicenter Data has been scarce for populations at the highest risk of infection, most notably immunosuppressed patients with underlying chronic inflammatory diseases or chronic use of anti-cytokine biologics and/or other immunomodulatory therapies We aimed to characterize the hospitalization and death rates among patients with inflammatory arthritis (IA;rheumatoid arthritis and spondyloarthritis) affected by COVID-19 and to analyze the associations between comorbidities and immunomodulatory medications and infection outcomes Methods: Recruitment stemmed from a larger NYU Langone Health study, namely Web-based Assessment of Autoimmune, Immune-Mediated, and Rheumatic Patients during the COVID-19 Pandemic (WARCOV) WARCOV is a prospective cohort of patients with established diagnosis of immune mediated inflammatory disease Participants were referred from 46 NYU affiliated providers throughout NYC Clinical, demographic, maintenance treatment, and disease course data and outcomes of individuals with IA with symptomatic COVID-19 were prospectively assessed via web-based questionnaire, individual phone calls, and electronic medical record review Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes were compared for each medication class using multivariable logistic regression Results: A total of 103 patients with IA were included in the study (n=80 confirmed and n=23 highly suspicious for COVID-19) 26% of participants required hospitalization, and 4% died Patients who warranted hospitalization were significantly more likely to be older (P< 0 001) and have comorbid hypertension (P=0 001) and chronic obstructive pulmonary disease (P=0 02) (Table) IA patients taking oral glucocorticoids had a higher likelihood of being admitted for COVID-19 (P< 0 001) while those on maintenance anti-cytokine biologic therapies did not After adjusting for age and sex, hypertension and oral glucocorticoid use remained significant risk factors for hospitalization (OR 3 33, 95% CI 1 16 to 9 60, P=0 03 and OR 21 12, 95% CI 4 09 to 109 03, P<0 001, respectively) Patients with rheumatoid arthritis were more likely to be hospitalized compared to those with spondyloarthritis, but were also older and more likely to be on oral glucocorticoids Conclusion: In patients with underlying IA, COVID-19 outcomes were worse in patients receiving glucocorticoids but, importantly, not in patients on maintenance anti-cytokine therapy As with non-IA patients, age and hypertension were also associated with hospitalization However, given our limitations of a relatively small number of hospitalizations and likely confounding by indication, caution should be taken in the interpretation of these results Further work, currently underway, is needed to better understand whether immunomodulatory therapies affect COVID-19 incidence and its natural history